Stockreport

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardle...

Esperion Therapeutics, Inc.  (ESPR) 
Last esperion therapeutics, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.esperion.com
PDF – New Labels Expand Treatable Population to ~70 Million Patients in U.S. –– First LDL-C Lowering Non-Statin Indicated for Primary Prevention Patients –– Approvals Based [Read more]